The medications Apretude and Cabenuva are both used in HIV care, but they serve different purposes. Apretude is used for HIV prevention (PrEP) in people who are HIV-negative, while Cabenuva is used to treat HIV in people who are already living with the virus.

This difference shapes how each medication is used and who it’s appropriate for.

That being said, it’s easy to see why these two medications get mixed up or grouped together. They share a few key traits:

  • Both are long-acting injections
  • Both are administered in a clinical setting
  • Both are used in HIV-related care
  • Both contain the medication cabotegravir

They also tend to show up in the same conversations online. You might see them mentioned in articles about new HIV treatments or prevention options, or in discussions about moving away from daily pills.

That overlap creates confusion. A lot of people assume they do the same thing, or that you can choose between them based on preference. But that is not how these medications are used.

So, even though they have some similarities on the surface, they’re designed for completely different situations.

The Most Important Difference: Prevention vs Treatment

This is the key point: Apretude is used to prevent HIV. Cabenuva is used to treat HIV in people who are already living with it.

That distinction matters more than anything else.

Apretude is part of PrEP, which stands for pre-exposure prophylaxis. It’s for people who do not have HIV but want protection against getting it.

Cabenuva is part of HIV treatment. It’s for people who have HIV and are managing it with medication, and it contains a combination of cabotegravir and rilpivirine.

A common question is whether Cabenuva can be used for PrEP, or if Apretude and Cabenuva are interchangeable. They are not.

Once you understand this, the rest of the comparison becomes much clearer.

What Apretude Is Used For (PrEP)

Apretude is an injectable form of PrEP. Its goal is simple: reduce your risk of getting HIV.

Instead of taking a daily pill, you receive an injection every two months after an initial start period. That makes it appealing for people who don’t want to think about a daily routine or who find it hard to stay consistent with pills.

Who it’s for

Apretude is for people who:

  • Do not have HIV
  • Want to reduce their risk getting HIV
  • Are eligible for PrEP based on their health and risk factors

This can include people with partners living with HIV, people with multiple partners, or anyone who wants an extra layer of protection.

How it works

Apretude contains cabotegravir, a medication that blocks HIV from establishing infection in the body. When levels of the drug are maintained through regular injections, it provides ongoing protection.

Unlike treatment medications like Cabenuva, which control an existing HIV infection, PrEP works ahead of exposure. It helps prevent HIV from establishing infection if exposure occurs.

What the schedule looks like

There are two ways Apretude may be started, depending on your provider’s recommendation.

Injection-only start

  • First injection
  • Second injection: 1 month later
  • After that: one injection every 2 months

Oral lead-in (optional)

Some people begin with a short course of oral cabotegravir to make sure the medication is well tolerated.

  • Oral cabotegravir tablets: once daily for about 1 month
  • Then first injection
  • Second injection: 1 month later
  • After that: one injection every 2 months

After the first two injections, Apretude is typically only needed every 2 months.

Before starting Apretude, you’ll need an HIV test to confirm you’re negative. Ongoing testing is also part of staying on PrEP safely, and it usually happens at your injection visits.

Keeping to the schedule is important to maintain protection.

The primary benefit of Apretude is HIV prevention. Compared to daily oral PrEP, one of the main advantages is consistency. You don’t have to remember a pill every day, and protection doesn’t depend on daily habits.

What Cabenuva Is Used For

Cabenuva is a treatment for people living with HIV. It’s designed to replace daily oral HIV medications with a long-acting injectable option.

Instead of taking pills every day, you receive injections once a month or every two months, depending on your treatment plan.

Who it’s for

Cabenuva is for people who:

  • Are living with HIV
  • Are already on treatment and have an undetectable viral load
  • Want an alternative to daily pills
  • Have no known resistance to its components

It’s not used to start treatment from scratch in most cases. It’s typically for people who are already stable on oral medication and want to switch.

What it does

Cabenuva is made up of two medications, cabotegravir and rilpivirine. Together, they suppress the HIV virus in the body.

The goal of HIV treatment is to maintain an undetectable viral load. When HIV is undetectable, it cannot be passed on to sexual partners. This is often referred to as U=U, or undetectable equals untransmittable.

Cabenuva helps maintain that suppression without the need for daily dosing. For some people, that also reduces stigma or the daily reminder of taking HIV medication.

What the schedule looks like

After an initial phase, injections are given either monthly or every two months.

Like Apretude, it requires regular clinic visits. These visits are part of ongoing care, not just medication delivery.

Canada note

Access to Apretude and Cabenuva in Canada may vary by province, including coverage and availability. A healthcare provider can help you understand what options are available where you live.

Why These Medications Are Sometimes Confused

Apretude and Cabenuva are often confused because they share some of the same components and are both long-acting injections used in HIV-related care.

But the intent behind each one is different.

Prevention and treatment are not interchangeable goals. Preventing HIV means stopping the virus before it takes hold. Treating HIV means managing a virus that is already present.

That’s why the medications are developed, tested, and approved separately. Even though they share some of the same components, they’re designed for completely different stages of care and aren’t used interchangeably.

They also both include cabotegravir as part of their formulation, which adds another layer of overlap.

Can Cabenuva Be Used for PrEP?

No, Cabenuva is not used for PrEP.

It is not approved for HIV prevention, and it hasn’t been designed for that purpose.

Even though it contains one of the same medications as Apretude, the combination and dosing are intended for treatment. Using it for prevention would not provide the same protection.

This is one of the most common questions people have, and it makes sense. If both are injections, it seems like they could be interchangeable.

But prevention and treatment require different approaches. Medications are tailored to those goals, and they are not swapped between them.

If you’re HIV-negative and looking for protection, Apretude or other PrEP options are what you’d consider, not Cabenuva.

How Clinicians Decide Which Medication Is Appropriate

The first question a clinician asks is simple: Do you have HIV?

That determines everything that follows.

If you do not have HIV

The focus is on prevention. A clinician will talk through your risk, your preferences, and your lifestyle.

Some people choose daily oral PrEP because it fits easily into their routine. Others prefer an option like Apretude, where protection is maintained through scheduled injections instead of daily action.

The decision often comes down to consistency. If remembering a pill every day feels like a barrier, a long-acting option may make more sense.

Access to a clinic also matters. Since Apretude requires regular appointments, it works best for people who can reliably attend those visits.

If you are living with HIV

The focus shifts to treatment. The priority is maintaining viral suppression and supporting long-term health.

If you’re stable on oral treatment and have an undetectable viral load, Cabenuva may be an option. Some people switch because they want fewer daily reminders of their medication. Others prefer the structure of scheduled appointments.

That said, it’s not the right fit for everyone. Missing injection appointments can impact how well the medication works, so consistency still matters, just in a different way.

Other factors that come into play

Beyond HIV status, clinicians also look at:

  • Your ability to attend regular appointments
  • Your comfort with injections
  • Your past experience with medications
  • Any side effects you’ve had before
  • Your overall health and other conditions

There isn’t a single “best” option. The right choice is the one you can stick with over time, whether that’s a daily pill or a long-acting injection.

If you’re exploring HIV prevention options like PrEP, a clinician can help you choose between injectable and oral options based on what fits your routine. Freddie offers virtual consultations to walk through your options and help you get started.

Frequently Asked Questions

Is Cabenuva the same as Apretude?

No, Cabenuva is not the same as Apretude. Apretude prevents HIV, while Cabenuva treats HIV. They are not the same.

Can Cabenuva prevent HIV?

No, Cabenuva is not approved for HIV prevention and should not be used as PrEP.

What is Apretude used for?

Apretude is used as PrEP to reduce the risk of getting HIV. It’s given as an injection every two months after the initial doses.

Can people with HIV take Apretude?

No, people with HIV cannot take Apretude. Apretude is only for people who are HIV-negative. It is not used to treat HIV.

Why are Cabenuva and Apretude both injections?

Canenuva and Apretude are both injections because both were developed as long-acting alternatives to daily pills. One is for prevention, and one is for treatment.

Which injection is used for PrEP?

Apretude is the injectable option used for PrEP.